Compare APAM & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APAM | IMNM |
|---|---|---|
| Founded | 1994 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2011 | 2020 |
| Metric | APAM | IMNM |
|---|---|---|
| Price | $42.78 | $25.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $43.00 | $32.80 |
| AVG Volume (30 Days) | 922.9K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 10.81% | N/A |
| EPS Growth | 10.66 | ★ 51.40 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $1,196,688,000.00 | $6,941,000.00 |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $5.05 | $1,127.34 |
| P/E Ratio | $22.47 | ★ N/A |
| Revenue Growth | ★ 7.63 | N/A |
| 52 Week Low | $33.96 | $8.67 |
| 52 Week High | $48.46 | $27.65 |
| Indicator | APAM | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 71.19 | 68.90 |
| Support Level | $42.64 | $19.28 |
| Resistance Level | $45.21 | $25.07 |
| Average True Range (ATR) | 1.17 | 1.08 |
| MACD | 0.32 | 0.15 |
| Stochastic Oscillator | 89.89 | 81.18 |
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. The company operates as one segment in the investment management business. The company generates maximum portion of its revenues from clients domiciled in countries outside the United States.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.